We are committed to advancing the treatment of eye conditions such as keratoconus and corneal ectasia following refractive surgery, through the continued innovation of our corneal cross-linking technology and pharmaceuticals. We develop products that are not only state-of-the-art but uphold the highest levels of quality and safety. Source
No articles found.
OrthoPediatrics currently markets greater than 30 surgical systems that serve thre...
OrthoPediatrics currently markets greater than ...
Soliton, Inc. is a medical device company with a novel and proprietary platform te...
Soliton, Inc. is a medical device company with ...
Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutio...
Allscripts (NASDAQ: MDRX) is a leader in health...
Fortress Biotech ("Fortress" or "the Company") is an innovative biopharmaceutical ...
Fortress Biotech ("Fortress" or "the Company") ...
Genocea is a biopharmaceutical company developing personalized cancer immunotherap...
Genocea is a biopharmaceutical company developi...
Omeros is a commercial-stage biopharmaceutical company committed to discovering, d...
Omeros is a commercial-stage biopharmaceutical ...
Microbotâ˘, which was founded in 2010 and commenced operations in 2011, became a ...
Microbotâ˘, which was founded in 2010 and comm...
Join the National Investor Network and get the latest information with your interests in mind.